RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem™ as a Treatment Option for Locally Advanced Pancreatic Cancer
RenovoRx today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer (“LAPC”).